Research Tracker›Biomarker Atlas›Multiple Sclerosis›GFAP

GFAP in Multiple Sclerosis

GFAP belongs to the neurological group of Multiple Sclerosis markers and is reported to be raised relative to the reference group of the cited comparison (progressive MS vs healthy/non-progressive). The source does not tie this marker to a specific symptom cluster, so it is best read as a biological signal rather than a symptom predictor. The evidence summarised here comes from Chitnis et al. 2025 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedNeurological

Summary

Direction in Multiple Sclerosis↑ Elevated — higher than in the comparison group
CategoryNeurological
Compared againstprogressive MS vs healthy/non-progressive
SourceChitnis et al. 2025 — doi:10.1016/S1474-4422(25)00249-2
Condition atlasMultiple Sclerosis Biomarker Atlas

Other conditions where GFAP is reported

See the cross-condition hub: GFAP across conditions.

Related Neurological markers in Multiple Sclerosis

Full list: Multiple Sclerosis Biomarker Atlas.

Frequently asked questions

Is GFAP high or low in Multiple Sclerosis?

Elevated. Studies summarised in the OSMF atlas report higher GFAP in Multiple Sclerosis than in the reference group of the cited comparison (progressive MS vs healthy/non-progressive). Source: Chitnis et al. 2025.

Which test measures GFAP?

The atlas record does not list a standardised clinical test code (LOINC) for GFAP, which usually means it was measured with research assays or study-specific protocols rather than a routine clinical panel. Check the cited source for the exact method.

Is one abnormal GFAP result diagnostic of Multiple Sclerosis?

No. No single biomarker is diagnostic of Multiple Sclerosis. GFAP findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is GFAP specific to Multiple Sclerosis?

No. The same marker is also reported in Long COVID in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). GFAP in Multiple Sclerosis: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/multiple-sclerosis/gfap.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-07-03 · Page generated from multiple-sclerosis.json · Browse: Multiple Sclerosis atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.